Clinical Trials
2 trialsNCT04285671 2026-03-10
Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT01763788 2019-10-25
A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 1/2 Completed